GRANULES - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.3
| Stock Code | GRANULES | Market Cap | 19,413 Cr. | Current Price | 784 ₹ | High / Low | 800 ₹ |
| Stock P/E | 47.4 | Book Value | 178 ₹ | Dividend Yield | 0.22 % | ROCE | 12.8 % |
| ROE | 10.5 % | Face Value | 1.00 ₹ | DMA 50 | 690 ₹ | DMA 200 | 603 ₹ |
| Chg in FII Hold | 1.76 % | Chg in DII Hold | -0.46 % | PAT Qtr | 99.0 Cr. | PAT Prev Qtr | 112 Cr. |
| RSI | 72.1 | MACD | 25.9 | Volume | 1,26,62,667 | Avg Vol 1Wk | 30,11,700 |
| Low price | 433 ₹ | High price | 800 ₹ | PEG Ratio | -7.39 | Debt to equity | 0.19 |
| 52w Index | 95.6 % | Qtr Profit Var | 36.1 % | EPS | 16.2 ₹ | Industry PE | 31.6 |
📊 GRANULES is trading at 784 ₹, well above its 50 DMA (690 ₹) and 200 DMA (603 ₹), confirming strong bullish momentum. RSI at 72.1 indicates overbought territory, suggesting risk of near-term profit booking. MACD at 25.9 is positive, reinforcing bullish bias. Bollinger Bands show price near the upper band, highlighting strong buying interest but also short-term volatility. Current volume (1,26,62,667) is significantly higher than the 1-week average (30,11,700), confirming strong participation and accumulation.
- 💰 Optimal Buy Price: 760 – 780 ₹ (support near breakout zone)
- 📈 Profit-Taking Exit Levels: 795 – 800 ₹ (near 52-week high resistance)
- 📉 Stop-Loss / Loss Protection: 740 ₹ (below support)
- ⏱️ Trend Status: Strong uptrend but nearing resistance; consolidation or profit booking likely.
Positive
✅ Price trading well above both 50 DMA and 200 DMA confirms bullish bias.
✅ RSI and MACD support strong momentum.
✅ FII holdings increased (+1.76%), showing foreign investor confidence.
✅ EPS at 16.2 ₹ provides a steady earnings base.
✅ Quarterly profit variation (+36.1%) highlights growth momentum.
Limitation
⚠️ RSI above 70 indicates overbought conditions.
⚠️ PEG ratio of -7.39 suggests weak growth prospects relative to valuation.
⚠️ ROCE (12.8%) and ROE (10.5%) are modest compared to peers.
⚠️ Dividend yield at 0.22% is negligible.
⚠️ PAT declined sequentially (99 Cr. vs 112 Cr.), showing earnings pressure.
Company Negative News
🚫 Sequential earnings decline raises concerns about sustainability.
🚫 DII holdings decreased (-0.46%), showing reduced domestic confidence.
🚫 Valuation concerns with P/E (47.4) above industry average (31.6).
Company Positive News
🌟 Strong quarterly profit variation (+36.1%) year-on-year.
🌟 FII inflows provide support for momentum.
🌟 Technical indicators confirm bullish bias near 52-week highs.
Industry
🏭 Industry P/E at 31.6 is lower than GRANULES’ 47.4, showing overvaluation relative to peers.
🏭 Pharma sector outlook remains positive with steady demand and export opportunities.
Conclusion
📌 GRANULES shows strong short-term bullish momentum supported by technical indicators and foreign inflows. However, weak fundamentals and stretched valuations limit long-term potential. Best strategy is cautious accumulation near 760 – 780 ₹ with profit booking around 795 – 800 ₹, maintaining a strict stop-loss near 740 ₹.
Would you like me to extend this into a peer benchmarking overlay with Divi’s Lab, Biocon, and Sun Pharma for comparative clarity, or keep the focus strictly on this standalone technical view?